Logo

Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies

Share this

Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies

Shots:
  • Themis to get global rights to develop- manufacture and commercialize therapies based on an oncolytic measles virus platform- collaborately developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry
  • The agreement focus on expanding immunomodulation portfolio for developing multiple immuno-oncology therapeutics
  • The licensed technology is based on the viral genome sequence of the measles vaccine strain used to immunize globally and can also be used for killing tumor cells
Ref: Themis Biosciences| Image: Themis Biosciences

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions